Novel azaheterocyclic amides useful for treating pain

Details for Australian Patent Application No. 2004257220 (hide)

Owner Abbott Laboratories

Inventors Brown, Brian S.; White, Tammie K.; Zheng, Guo Zhu; Koenig, John R.; Lee, Chih-Hung; Turner, Sean C.; Schmidt, Robert G.

Agent Spruson & Ferguson

Pub. Number AU-A-2004257220

PCT Pub. Number WO2005/007642

Priority 10/618,016 11.07.03 US

Filing date 9 July 2004

Wipo publication date 27 January 2005

International Classifications

C07D 401/04 (2006.01) Heterocyclic compounds containing two or more hetero rings

A61K 31/4525 (2006.01)

A61K 31/4995 (2006.01) - Pyrazines or piperazines forming part of bridged ring systems

A61P 25/04 (2006.01) Drugs for disorders of the nervous system

C07D 401/12 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 487/08 (2006.01) Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups

Event Publications

9 February 2006 PCT application entered the National Phase

  PCT publication WO2005/007642 Priority application(s): WO2005/007642

3 February 2011 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(d). Examination has been requested or an examination report has issued for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004257221-Method and apparatus for flatproofing a tire and wheel assembly and resulting flatproofed assembly

2004257214-Alphavirus-based cytomegalovirus vaccines